What is he best known for?
The fields of study he is best known for:
- Cancer
- Gene
- Internal medicine
Ignacio I. Wistuba focuses on Lung cancer, Cancer research, Adenocarcinoma, Cancer and Pathology.
His Lung cancer research incorporates elements of Carcinoma, Lung and Epidermal growth factor receptor.
His study in Cancer research is interdisciplinary in nature, drawing from both Mutation, KRAS, Molecular biology and microRNA.
His Adenocarcinoma study integrates concerns from other disciplines, such as Carcinogenesis, Epithelial–mesenchymal transition, Small Cell Lung Carcinoma and Loss of heterozygosity.
Ignacio I. Wistuba has included themes like Biomarker, Blockade and Bioinformatics in his Cancer study.
His work investigates the relationship between Pathology and topics such as Cell that intersect with problems in Vimentin, Adenocarcinoma of the lung and Cell growth.
His most cited work include:
- International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma (3017 citations)
- Somatic mutations affect key pathways in lung adenocarcinoma (2148 citations)
- Clinical and Biological Features Associated With Epidermal Growth Factor Receptor Gene Mutations in Lung Cancers (1884 citations)
What are the main themes of his work throughout his whole career to date?
His main research concerns Lung cancer, Cancer research, Cancer, Internal medicine and Pathology.
His Lung cancer study combines topics from a wide range of disciplines, such as KRAS, Carcinoma, Lung and Adenocarcinoma.
The Cancer research study combines topics in areas such as Cell, Carcinogenesis, Cancer cell, Immune system and Metastasis.
His Cancer research includes themes of PI3K/AKT/mTOR pathway, Immunology and Bioinformatics.
The study incorporates disciplines such as Gastroenterology and Oncology in addition to Internal medicine.
His work carried out in the field of Oncology brings together such families of science as Stage and Biomarker.
He most often published in these fields:
- Lung cancer (47.48%)
- Cancer research (46.05%)
- Cancer (29.93%)
What were the highlights of his more recent work (between 2018-2021)?
- Cancer research (46.05%)
- Lung cancer (47.48%)
- Internal medicine (27.96%)
In recent papers he was focusing on the following fields of study:
Ignacio I. Wistuba mainly focuses on Cancer research, Lung cancer, Internal medicine, Oncology and Immune system.
His work deals with themes such as Immune checkpoint, Immunotherapy, T cell and Adenocarcinoma, which intersect with Cancer research.
His Adenocarcinoma research is multidisciplinary, incorporating perspectives in Carcinogenesis, Lung and Pathology.
His research in Lung cancer is mostly concerned with Non small cell.
His Oncology study which covers Nivolumab that intersects with Ipilimumab.
Ignacio I. Wistuba interconnects Computational biology and Disease in the investigation of issues within Cancer.
Between 2018 and 2021, his most popular works were:
- Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer (183 citations)
- Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients With Incurable Human Papillomavirus 16-Related Cancer: A Phase 2 Clinical Trial. (137 citations)
- Best Practices Recommendations for Diagnostic Immunohistochemistry in Lung Cancer (80 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Gene
- Internal medicine
His scientific interests lie mostly in Lung cancer, Cancer research, Internal medicine, Oncology and Immunotherapy.
His study with Lung cancer involves better knowledge in Pathology.
His biological study spans a wide range of topics, including Thyroid and Adenocarcinoma.
The study incorporates disciplines such as Cell, Cancer cell, T cell, Immune system and Metastasis in addition to Cancer research.
His studies deal with areas such as Chemotherapy, Nivolumab, Atezolizumab, Immune checkpoint inhibitors and Major Pathologic Response as well as Oncology.
His study in Immunotherapy is interdisciplinary in nature, drawing from both Immunohistochemistry and Targeted therapy.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
